Metabolic syndrome negatively impacts the outcome of localized renal cell carcinoma

• Verfasst von: Kriegmair, Maximilian [VerfasserIn]
• Verfasst von: Porubský, Štefan [VerfasserIn]
• Verfasst von: Dürr, Julia [VerfasserIn]
• Verfasst von: Younsi, Nina [VerfasserIn]
• Verfasst von: Nuhn, Philipp [VerfasserIn]
• Verfasst von: Pfalzgraf, Daniel Philipp [VerfasserIn]
• Verfasst von: Michel, Maurice Stephan [VerfasserIn]
• Verfasst von: Wagener, Nina [VerfasserIn]
• Titel: Metabolic syndrome negatively impacts the outcome of localized renal cell carcinoma
• Verf.angabe: Maximilian Christian Kriegmair, Philipp Mandel, Stefan Porubsky, Julia Dürr, Nina Huck, Philipp Nuhn, Daniel Pfalzgraf, Maurice Stephan Michel, Nina Wagener
• Jahr: 2017
• Umfang: 8 S.
• Fussnoten: First Online: 28 February 2017 ; Gesehen am 19.06.2018
• Titel Quelle: Enthalten in: Hormones and cancer
• Ort Quelle: New York, NY [u.a.] : Springer, 2010
• Jahr Quelle: 2017
• Band/Heft Quelle: 8(2017), 2, Seite 127-134
• ISSN Quelle: 1868-8500
• DOI: doi:10.1007/s12672-017-0289-2
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1576500446

Abstract

The aim of this study was to analyze the impact of metabolic syndrome (MetS) on outcome of patients with localized renal cell carcinoma (RCC). A retrospective database was compiled consisting of 646 patients who underwent surgery for localized RCC between 2005 and 2014. A total of 439 patients were eligible for final analysis. For diagnosis of MetS, the WHO criteria of 1998 were used. Median follow-up was 32 months (ranging from 2 to 119). Kaplan-Meier and log-rank analyses were performed to compare patients with and without MetS or its components. Univariate and multivariate logistic regression identified prognostic factors for progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). In our cohort, 9.8% (n = 43) of patients were diagnosed with MetS. There were no differences between patients with and without MetS regarding clinicopathological parameters with the exception of patients’ age (p = 0.002). Kaplan-Meier and log-rank analyses revealed a shorter PFS for patients with MetS (p = 0.018), whereas no differences were found for each of the single components of MetS, namely, diabetes mellitus (DM) (p = 0.332), BMI >30 kg/m2 (p = 0.753), hypertension (p = 0.451), and hypertriglyceridemia (p = 0.891). Logistic regression identified age (HR = 1.92, p = 0.03), tumor stage (HR = 4.37, p < 0.001), grading (HR = 4.57, p < 0.001), nodal status (HR = 3.73, p = 0.04), surgical margin (HR = 1.96, p = 0.04), concomitant sarcomatoid differentiation (HR = 5.06, p < 0.001), and MetS (HR = 1.98, p = 0.04) as independent factors for PFS. For CSS, only age (HR = 2.62, p = 0.035), tumor stage (HR = 3.06, p < 0.02), and grading (HR = 6.83, p < 0.001) were significant. In conclusion, patients with localized RCC and MetS show significantly reduced PFS and might profit from specific consultation and follow-up.